This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Proteintech Group
product type :
antibody
product name :
RRM1
catalog :
10526-1-AP
quantity :
150UL
price :
299 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
citations: 19
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; loading ...; fig 1a
Lou M, Liu Q, Ren G, Zeng J, Xiang X, Ding Y, et al. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem. 2017;292:9136-9149 pubmed publisher
  • immunohistochemistry - paraffin section; human; loading ...; tbl 2
Herzog T, Spetzler D, Xiao N, Burnett K, Maney T, Voss A, et al. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget. 2016;7:19840-9 pubmed publisher
Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, et al. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Am J Cancer Res. 2020;10:1182-1193 pubmed
Ding Y, Zhong T, Wang M, Xiang X, Ren G, Jia Z, et al. Integrative Analysis Reveals Across-Cancer Expression Patterns and Clinical Relevance of Ribonucleotide Reductase in Human Cancers. Front Oncol. 2019;9:956 pubmed publisher
Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas D, Kurzrock R. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer. 2019;: pubmed publisher
Sun Q, Xu W, Ji S, Qin Y, Liu W, Hu Q, et al. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell Int. 2019;19:49 pubmed publisher
Woo S, Yoon K, Hong E, Park W, Han S, Park S, et al. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. Oncotarget. 2017;8:81394-81404 pubmed publisher
Toth C, Sukosd F, Valicsek E, Herpel E, Schirmacher P, Renner M, et al. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer. Int J Mol Med. 2017;40:1457-1465 pubmed publisher
Hu Q, Qin Y, Zhang B, Liang C, Ji S, Shi S, et al. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncol Rep. 2017;38:2069-2077 pubmed publisher
Liu D, Nakashima N, Nakano J, Tarumi S, Matsuura N, Nakano T, et al. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer. Anticancer Res. 2017;37:2501-2507 pubmed
Matsumura N, Nakamura Y, Kohjimoto Y, Nishizawa S, Kikkawa K, Iba A, et al. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy. Int J Urol. 2017;24:230-235 pubmed publisher
Millis S, Ejadi S, Demeure M. Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. Biomark Cancer. 2015;7:69-76 pubmed publisher
Zimling Z, Santoni Rugiu E, Bech C, Sørensen J. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. Anticancer Res. 2015;35:6731-8 pubmed
Popovtzer A, Sarfaty M, Limon D, Marshack G, Perlow E, Dvir A, et al. Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy. Biomed Res Int. 2015;2015:614845 pubmed publisher
Vena F, Li Causi E, Rodriguez Justo M, Goodstal S, Hagemann T, Hartley J, et al. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). Clin Cancer Res. 2015;21:5563-77 pubmed publisher
Kim M, Ku J, Kwak C, Kim H, Lee E, Keam B, et al. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE. 2015;10:e0133371 pubmed publisher
Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, et al. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. J Thorac Cardiovasc Surg. 2015;149:1539-46.e1 pubmed publisher
Watanabe Y, Shiraishi K, Takahashi F, Yoshida A, Suzuki K, Asamura H, et al. Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma. Histopathology. 2015;66:939-48 pubmed publisher
Millis S, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer. 2015;13:e37-49 pubmed publisher
product information
CatalogNo :
10526-1-AP
AntigenName :
RRM1
Package :
150UL
Price :
299 USD
Exsists20ul :
20ul trial size available
FullName :
ribonucleotide reductase M1
Immunogen :
Recombinant Protein
Species :
human, xenopus
Host :
Rabbit
IsConjugated :
Unconjugated
AntigenSpecies :
human
Application :
WB, IP, IHC, IF, FC, ELISA
Clonlity :
Polyclonal
IsoType :
IgG
Synonyms :
R1, ribonucleotide reductase M1, RIR1, RR1, RRM1
PrimaryOrSecondary :
Primary
AntibodyBuffer :
PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
GenBankNo :
BC006498
Category :
Binding Proteins;Cell Cycle;Disease Related;IVD;Metabolism;
PurifyMethod :
Antigen affinity purification
NewAb :
False
IsSellable :
True
Feature :
siRNA
AppTiter :
FC 1:0 ; IF 1:50 ; IHC 1:200 ; IP 1:800 ; WB 1:2000 ;
company information
Proteintech Group
2201 W. Campbell Park Dr. STE12
Chicago, IL 60612
Proteintech@ptglab.com
https://www.ptglab.com
1-312-455-8498
headquarters: USA
At Proteintech, we produce every single antibody we sell; we do not rely on or supply to any other antibody providers: our products are unique and we are 100% accountable for each one. We realize this accountability by validating in-house, providing extensive technical support and guaranteeing your success: in addition to helping you troubleshoot your experiment, we will offer you a full cash refund if you are in any way dissatisfied. We can guarantee satisfaction because we have confidence in our products, confidence cultivated by the science behind our antibodies: we make them using as much of the native protein as possible, and purifying them using affinity purification with the original antigen. We carry out antibody production over a 102-day period, which allows for better antigen fitting to MHC molecules and affinity maturation in the host. This approach results in higher affinity antibodies with greater sensitivity, which you can use in any application and in multiple species.
You can only buy Proteintech antibodies directly from Proteintech or via one of its approved distributors — when you receive your antibody and see the Proteintech logo on the vial, know that you hold something that is truly unique.